Multifunctional Cationic Hyperbranched Polyaminoglycosides that Target Multiple Mediators for Severe Abdominal Trauma

Yongqiang Xiao1,2,3, He Fang1, Yuefei Zhu2

  • 1Department of Burn Surgery, the First Affiliated Hospital, Naval Medical University, Shanghai, 200433, P. R. China.

Insights

New biomaterials, hyperbranched polyaminoglycosides (HPT and ss-HPT), effectively scavenge cell-free nucleic acids (cfNAs) to reduce post-trauma inflammation and coagulation. The ss-HPT variant shows promising targeted delivery and biodegradation for improved trauma patient outcomes.

Area of Science:

  • Biomaterials Science
  • Immunology
  • Trauma Pathophysiology

Background:

  • Trauma triggers severe complications like inflammation, infection, and DIC due to cell-free nucleic acids (cfNAs) acting as damage-associated molecular patterns (DAMPs).
  • Biomaterial-based cfNA scavenging offers a potential therapeutic strategy to mitigate post-trauma systemic inflammation and coagulation abnormalities.

Purpose of the Study:

  • To investigate the efficacy of cationic hyperbranched polyaminoglycosides (HPT) and disulfide-included HPT (ss-HPT) in scavenging cfNAs.
  • To evaluate their potential in mitigating post-trauma inflammation and hypercoagulation.

Main Methods:

  • Synthesis of HPT and ss-HPT polymers derived from tobramycin.
  • In vitro assessment of cfNA scavenging, DAMP-induced TLR activation, inflammatory cytokine secretion, and hypercoagulation.
  • In vivo evaluation in a cecal ligation puncture (CLP) mouse abdominal trauma model, including organ accumulation, retention, and biodegradation studies.

Main Results:

  • Both HPT and ss-HPT effectively scavenged cfNAs, suppressing TLR activation, cytokine release, and hypercoagulation.
  • Polymers demonstrated antibacterial activity due to tobramycin.
  • In the CLP model, HPT and ss-HPT modulated inflammation and improved therapeutic outcomes.
  • ss-HPT showed enhanced accumulation in injured organs and faster biodegradation in healthy mice compared to HPT.

Conclusions:

  • Functionalized ss-HPT, a bioreducible polyaminoglycoside, effectively scavenges cfNAs and exhibits therapeutic potential.
  • ss-HPT holds promise for enhancing trauma patient outcomes by reducing inflammation and coagulation complications.

Related Concept Videos

Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
830
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
211
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
183
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
221